2. Orbomed team
Vitaly Vishnepolsky, MBA CEO Dr. Vadim Sigalov, MD
Chief Business consultant Chief Medical consultant
Ksenia Chagan, MBA Igor Shcherback, PhD
Biotech advisor Physics advisor
3. Hysteroscopy: background
• Gold standard for detection
of intrauterine pathology
• Safe and simple procedure
for outpatient clinics
4. Hysteroscopy: background (cont.)
• From patients’ side pain continues to
represent the main limiting factor to a
large-scale use of outpatient hysteroscopy
5. Office Based Hysteroscopy
(OBH) facts
• Only 15% of gynecologists in the United States
routinely perform office hysteroscopy to evaluate
intrauterine pathology.
Reimbursement
Equipment
6. The OBH need
• Broadening of applications’ list
• Cost reduction
• Becoming the gold standard
for specific operations
• Updating of reimbursement
policies.
7. Orbomed:
Office Based Hysteroscopy product line
• Three dimensional scissors
• No need for laparoscop reposition
• Easier lesion capture in moving media (saline flow)
• Ready-for-sending tissue sample post-operationally
8. What is the difference in
ORBOMED concept?
VIDEO>>
9. Advantages of Orbomed
• Improved patient’s comfort
• Eliminated need for general anesthesia
• Shorten interventional procedure
• Reduced overall cost
11. Applications
• Polypectomy – 6M of annual visits
• Adhesiolysis – 1M of Asherman Syndrome
• Biopsy under direct visualization – approx. 50K
of new endometrial cancer/year
12. Market potential
• Global Uro-Gynecological
Surgical Devices Market to
Reach US$1.98 Billion by
2015
• Global Biopsy devices
Market is expected to
reach $1.4 Billion by 2018,
CAGR 5% from 2011.
13. Orbomed R&D plan
• Within 24 months we plan to achieve fully
working prototype ready for clinical trials
• Planned budget $750K
